Description

Airtio-F Instacaps is a dual bronchodilator therapy used in the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It combines Formoterol, a long-acting beta-agonist (LABA) that relaxes airway muscles and improves airflow, with Tiotropium, a long-acting muscarinic antagonist (LAMA) that prevents airway narrowing. This dual-action approach provides superior symptom control, reduces flare-ups, and improves lung function in patients with moderate to severe COPD.

Uses

Long-term treatment of COPD (chronic bronchitis, emphysema)
Helps relieve breathlessness, wheezing, and chest tightness
Improves exercise capacity and lung performance
Reduces frequency of COPD exacerbations and hospital visits

Dosage

Usually prescribed as 1 inhalation daily, or as directed by the doctor.
Must be taken regularly at the same time for best results.
Not suitable for sudden breathing attacks (rescue medication required for emergencies).

Possible Side Effects

Dry mouth or throat irritation
Headache or dizziness
Cough or hoarseness
Constipation or urinary difficulty (rare)
Palpitations or tremors (uncommon)

About the Company

Glenmark Pharmaceuticals Ltd is a trusted Indian multinational pharmaceutical company with a strong presence in respiratory medicine. Their inhalation therapies and instacap technology are widely prescribed for asthma and COPD, offering effective and affordable solutions to patients worldwide.

Good Things About Airtio-F

Provides dual bronchodilation (LABA + LAMA) for maximum airway relaxation
Offers 24-hour symptom relief with once-daily dosing
Reduces dependence on rescue medications
Enhances patient’s ability to perform daily activities with less breathlessness
Manufactured by Glenmark, known for innovation and affordability in respiratory care